메뉴 건너뛰기




Volumn 146, Issue 7, 2014, Pages

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial

(16)  Forns, Xavier a   Lawitz, Eric b   Zeuzem, Stefan c   Gane, Ed d   Bronowicki, Jean Pierre e   Andreone, Pietro f   Horban, Andrzej g   Brown, Ashley h   Peeters, Monika i   Lenz, Oliver i   Ouwerkerk Mahadevan, Sivi j   Scott, Jane k   De La Rosa, Guy l   Kalmeijer, Ronald l   Sinha, Rekha i   Beumont Mauviel, Maria i  


Author keywords

Chronic Hepatitis C; DAA; Drug; PROMISE

Indexed keywords

BILIRUBIN; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; SIMEPREVIR; VIRUS RNA;

EID: 84901217985     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.02.051     Document Type: Article
Times cited : (222)

References (43)
  • 1
    • 77951440698 scopus 로고    scopus 로고
    • World Health Organization Accessed June 20, 2013
    • World Health Organization. WHO fact sheet 164-hepatitis C. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed June 20, 2013.
    • WHO Fact Sheet 164-hepatitis C
  • 2
    • 79960453276 scopus 로고    scopus 로고
    • EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
    • European Association for the Study of the Liver
    • European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
    • (2011) J Hepatol , vol.55 , pp. 245-264
  • 3
    • 80053339008 scopus 로고    scopus 로고
    • An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
    • M.G. Ghany, D.R. Nelson, and D.B. Strader et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
    • (2011) Hepatology , vol.54 , pp. 1433-1444
    • Ghany, M.G.1    Nelson, D.R.2    Strader, D.B.3
  • 4
    • 84862850805 scopus 로고    scopus 로고
    • APASL consensus statements and management algorithms for hepatitis C infection
    • M. Omata, T. Kanda, and M.-L. Yu et al. APASL consensus statements and management algorithms for hepatitis C infection Hepatol Int 6 2012 409 435
    • (2012) Hepatol Int , vol.6 , pp. 409-435
    • Omata, M.1    Kanda, T.2    Yu, M.-L.3
  • 5
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • M.W. Fried, M.L. Shiffman, and K.R. Reddy et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 6
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • M.P. Manns, J.G. McHutchison, and S.C. Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 7
    • 68249154875 scopus 로고    scopus 로고
    • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    • J.G. McHutchison, E.J. Lawitz, and M.L. Shiffman et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
    • (2009) N Engl J Med , vol.361 , pp. 580-593
    • McHutchison, J.G.1    Lawitz, E.J.2    Shiffman, M.L.3
  • 8
    • 33745214494 scopus 로고    scopus 로고
    • Re-treatment of chronic hepatitis C patients after relapse: Efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin
    • C. Berg, F.L. Goncales Jr., and D.E. Bernstein et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin J Viral Hepat 13 2006 435 440
    • (2006) J Viral Hepat , vol.13 , pp. 435-440
    • Berg, C.1    Goncales, Jr.F.L.2    Bernstein, D.E.3
  • 9
    • 70449408989 scopus 로고    scopus 로고
    • Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin
    • D.T. Dieterich, M. Rizzetto, and M.P. Manns Management of chronic hepatitis C patients who have relapsed or not responded to pegylated interferon alfa plus ribavirin J Viral Hepat 16 2009 833 843
    • (2009) J Viral Hepat , vol.16 , pp. 833-843
    • Dieterich, D.T.1    Rizzetto, M.2    Manns, M.P.3
  • 10
    • 67349172961 scopus 로고    scopus 로고
    • Peginterferon alfa-2b and ribavirin: Effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy
    • T. Poynard, M. Colombo, and J. Bruix et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
    • (2009) Gastroenterology , vol.136 , pp. 1618-1628
    • Poynard, T.1    Colombo, M.2    Bruix, J.3
  • 11
    • 79953176289 scopus 로고    scopus 로고
    • Boceprevir for previously treated chronic HCV genotype 1 infection
    • B.R. Bacon, S.C. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
    • (2011) N Engl J Med , vol.364 , pp. 1207-1217
    • Bacon, B.R.1    Gordon, S.C.2    Lawitz, E.3
  • 12
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 13
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
    • (2011) N Engl J Med , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone, Jr.J.2    Bacon, B.R.3
  • 14
    • 79959381354 scopus 로고    scopus 로고
    • Telaprevir for retreatment of HCV infection
    • S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
    • (2011) N Engl J Med , vol.364 , pp. 2417-2428
    • Zeuzem, S.1    Andreone, P.2    Pol, S.3
  • 15
    • 80052826527 scopus 로고    scopus 로고
    • Response-guided telaprevir combination treatment for hepatitis C virus infection
    • K.E. Sherman, S.L. Flamm, and N.H. Afdhal et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
    • (2011) N Engl J Med , vol.365 , pp. 1014-1024
    • Sherman, K.E.1    Flamm, S.L.2    Afdhal, N.H.3
  • 16
    • 33644636312 scopus 로고    scopus 로고
    • Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
    • R.B. Perni, S.J. Almquist, and R.A. Byrn et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 2006 899 909
    • (2006) Antimicrob Agents Chemother , vol.50 , pp. 899-909
    • Perni, R.B.1    Almquist, S.J.2    Byrn, R.A.3
  • 17
    • 84901233284 scopus 로고    scopus 로고
    • Accessed February 3, 2014
    • RxList. Victrelis. Available at: http://www.rxlist.com/victrelis-drug/ clinical-pharmacology.htm. Accessed February 3, 2014.
    • RxList. Victrelis
  • 18
    • 84885871290 scopus 로고    scopus 로고
    • OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients
    • M. Buti, K. Agarwal, and Y. Horsmans et al. OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients Hepatology 56 2012 191A 1144A
    • (2012) Hepatology , vol.56
    • Buti, M.1    Agarwal, K.2    Horsmans, Y.3
  • 19
    • 84864206329 scopus 로고    scopus 로고
    • Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C
    • X. Gao, J.M. Stephens, and J.A. Carter et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 2012 335 343
    • (2012) Expert Rev Pharmacoecon Outcomes Res , vol.12 , pp. 335-343
    • Gao, X.1    Stephens, J.M.2    Carter, J.A.3
  • 20
    • 84855244456 scopus 로고    scopus 로고
    • Boceprevir and telaprevir for the treatment of chronic hepatitis C: Safety management in clinical practice
    • C. Hezode Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice Liver Int 32 Suppl 1 2012 32 38
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 32-38
    • Hezode, C.1
  • 21
    • 84882908504 scopus 로고    scopus 로고
    • Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890
    • C. Hezode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC)-NCT01514890 J Hepatol 59 2013 434 441
    • (2013) J Hepatol , vol.59 , pp. 434-441
    • Hezode, C.1    Fontaine, H.2    Dorival, C.3
  • 22
    • 84865454706 scopus 로고    scopus 로고
    • Safety of telaprevir for chronic hepatitis C virus infection: A meta-analysis of randomized controlled trials
    • H. Qin, H. Li, and X. Zhou et al. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials Clin Drug Investig 32 2012 665 672
    • (2012) Clin Drug Investig , vol.32 , pp. 665-672
    • Qin, H.1    Li, H.2    Zhou, X.3
  • 26
    • 84901188907 scopus 로고    scopus 로고
    • Janssen Products, LP Accessed January 22, 2014
    • TM - Highlights of prescribing information. Available at: http://www.olysio.com/shared/product/olysio/ prescribing-information.pdf. Accessed January 22, 2014.
    • TM - Highlights of Prescribing Information
  • 27
    • 84888295678 scopus 로고    scopus 로고
    • Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study
    • M.W. Fried, M. Buti, and G.J. Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
    • (2013) Hepatology , vol.58 , pp. 1918-1929
    • Fried, M.W.1    Buti, M.2    Dore, G.J.3
  • 28
    • 84861188748 scopus 로고    scopus 로고
    • Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study
    • C. Moreno, T. Berg, and T. Tanwandee et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
    • (2012) J Hepatol , vol.56 , pp. 1247-1253
    • Moreno, C.1    Berg, T.2    Tanwandee, T.3
  • 29
    • 77449158033 scopus 로고    scopus 로고
    • Rapid HCV-RNA decline with once daily TMC435: A phase i study in healthy volunteers and hepatitis C patients
    • H.W. Reesink, G.C. Fanning, and K.A. Farha et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
    • (2010) Gastroenterology , vol.138 , pp. 913-921
    • Reesink, H.W.1    Fanning, G.C.2    Farha, K.A.3
  • 30
    • 84892806505 scopus 로고    scopus 로고
    • Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial
    • S. Zeuzem, T. Berg, and E. Gane et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2013 430 441.e6
    • (2013) Gastroenterology , vol.146
    • Zeuzem, S.1    Berg, T.2    Gane, E.3
  • 31
    • 84895736477 scopus 로고    scopus 로고
    • SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study
    • abstract LB-3
    • Jacobson IM, Ghalib R, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013;58:1379A, abstract LB-3.
    • (2013) Hepatology , vol.58
    • Jacobson, I.M.1    Ghalib, R.2    Rodriguez-Torres, M.3
  • 32
    • 80055076797 scopus 로고    scopus 로고
    • Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: A randomized trial
    • M. Manns, H. Reesink, and T. Berg et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 2011 1021 1033
    • (2011) Antivir Ther , vol.16 , pp. 1021-1033
    • Manns, M.1    Reesink, H.2    Berg, T.3
  • 33
    • 84901233285 scopus 로고    scopus 로고
    • Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-2, a phase III trial
    • press
    • Manns M, Marcellin P, Poordad F, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet, in press.
    • Lancet
    • Manns, M.1    Marcellin, P.2    Poordad, F.3
  • 34
    • 84901233286 scopus 로고    scopus 로고
    • Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: Results from QUEST-1, a phase III trial
    • press
    • Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. Lancet, in press.
    • Lancet
    • Jacobson, I.1    Dore, G.J.2    Foster, G.R.3
  • 35
    • 0034533990 scopus 로고    scopus 로고
    • Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C
    • L. Kleinman, M.W. Zodet, and Z. Hakim et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C Qual Life Res 9 2000 499 508
    • (2000) Qual Life Res , vol.9 , pp. 499-508
    • Kleinman, L.1    Zodet, M.W.2    Hakim, Z.3
  • 36
    • 0027693577 scopus 로고
    • The validity and reproducibility of a work productivity and activity impairment instrument
    • M.C. Reilly, A.S. Zbrozek, and E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
    • (1993) Pharmacoeconomics , vol.4 , pp. 353-365
    • Reilly, M.C.1    Zbrozek, A.S.2    Dukes, E.M.3
  • 37
    • 77950817619 scopus 로고    scopus 로고
    • Telaprevir for previously treated chronic HCV infection
    • J.G. McHutchison, M.P. Manns, and A.J. Muir et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
    • (2010) N Engl J Med , vol.362 , pp. 1292-1303
    • McHutchison, J.G.1    Manns, M.P.2    Muir, A.J.3
  • 38
    • 79951794050 scopus 로고    scopus 로고
    • Response-guided therapy for HCV
    • P.Y. Kwo Response-guided therapy for HCV Gastroenterol Hepatol (N Y) 7 2011 43 45
    • (2011) Gastroenterol Hepatol (N Y) , vol.7 , pp. 43-45
    • Kwo, P.Y.1
  • 39
    • 84901238396 scopus 로고    scopus 로고
    • Cost benefit analysis of response guided therapy: Dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages
    • abs 1167
    • P. McEwan, Y. Yuan, and G. Litauen et al. Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages J Hepatol 54 2011 S461 abs 1167
    • (2011) J Hepatol , vol.54 , pp. 461
    • McEwan, P.1    Yuan, Y.2    Litauen, G.3
  • 40
    • 84855219530 scopus 로고    scopus 로고
    • Response-guided and -unguided treatment of chronic hepatitis C
    • K.R. Reddy, F. Lin, and F. Zoulim Response-guided and -unguided treatment of chronic hepatitis C Liver Int 32 Suppl 1 2012 64 73
    • (2012) Liver Int , vol.32 , Issue.SUPPL. 1 , pp. 64-73
    • Reddy, K.R.1    Lin, F.2    Zoulim, F.3
  • 42
    • 33750369259 scopus 로고    scopus 로고
    • Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy
    • M. Sherman, E.M. Yoshida, and M. Deschenes et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy Gut 55 2006 1631 1638
    • (2006) Gut , vol.55 , pp. 1631-1638
    • Sherman, M.1    Yoshida, E.M.2    Deschenes, M.3
  • 43
    • 81855188786 scopus 로고    scopus 로고
    • In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters
    • abstract 278
    • Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology 2010;52:461A, abstract 278.
    • (2010) Hepatology , vol.52
    • Huisman, M.T.1    Snoeys, J.2    Monbaliu, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.